In a reversal, investigators for a trial comparing Biotronik‘s bioresorbable, drug-eluting Orsiro stent and Biosensors‘ BioFreedom drug-eluting stent reported this week that Biosensors’ device did not meet the criteria for noninferiority.
The researchers said that while preparing the study for publication in a journal, they discovered a statistical error that ultimately changed the trial’s conclusion. The results were first presented earlier this year at the 2018 Transcatheter Cardiovascular Therapeutics meeting.
Get the full story at our sister site, Drug Delivery Business News.
The post Statistical error reverses noninferiority finding in head-to-head trial of DES, bioresorbable scaffold appeared first on MassDevice.